Stockscreener 앱 받기
13.91
0.58%
0.08
전일 마감가:
$13.83
열려 있는:
$13.68
하루 거래량:
1.05M
Relative Volume:
0.56
시가총액:
$990.25M
수익:
-
순이익/손실:
$-34.98M
주가수익비율:
-15.12
EPS:
-0.9199
순현금흐름:
$-32.77M
1주 성능:
-0.22%
1개월 성능:
+49.09%
6개월 성능:
+62.50%
1년 성능:
+535.16%
1일 변동 폭
$13.60
$14.09
1주일 범위
$13.42
$14.26
52주 변동 폭
$1.94
$15.10
Immix Biopharma Inc Stock (IMMX) Company Profile
명칭
Immix Biopharma Inc
전화
(888) 958-1084
주소
11400 WEST OLYMPIC BLVD., LOS ANGELES
Compare IMMX vs VRTX, REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IMMX
Immix Biopharma Inc
|
13.91 | 936.86M | 0 | -34.98M | -32.77M | -0.9199 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Immix Biopharma Inc Stock (IMMX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-25 | 개시 | Morgan Stanley | Overweight |
| 2026-03-09 | 개시 | Citizens | Mkt Outperform |
| 2026-02-09 | 개시 | Mizuho | Outperform |
Immix Biopharma Inc 주식(IMMX)의 최신 뉴스
Tocqueville Asset Management L.P. Buys New Position in Immix Biopharma, Inc. $IMMX - MarketBeat
Blue Owl Capital Holdings LP Makes New $4.51 Million Investment in Immix Biopharma, Inc. $IMMX - MarketBeat
Immix Biopharma (NASDAQ:IMMX) Sets New 12-Month HighStill a Buy? - MarketBeat
Immix Biopharma Stock Price Forecast. Should You Buy IMMX? - StockInvest.us
Immix Biopharma (NASDAQ:IMMX) Stock Price Down 4.5%Here's Why - MarketBeat
Immix Biopharma (IMMX) gains 5.6% stake holder led by Eventide Asset Management - Stock Titan
Citizens reiterates Immix Biopharma stock rating on pipeline progress By Investing.com - Investing.com Australia
Citizens reiterates Immix Biopharma stock rating on pipeline progress - Investing.com
Morgan Stanley Adjusts PT on Immix Biopharma to $19 From $20, Maintains Overweight Rating - Moomoo
Janus Henderson Group (IMMX) discloses 9.78M-share beneficial stake in Immix Biopharma - Stock Titan
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immix Biopharma, Inc.IMMX - PR Newswire
Immix Biopharma Q3 EPS Estimate Lowered by HC Wainwright - MarketBeat
Immix Biopharma (NASDAQ:IMMX) Trading 7.1% HigherStill a Buy? - MarketBeat
HC Wainwright Estimates Immix Biopharma FY2027 Earnings - MarketBeat
Immix Biopharma publishes corporate presentation on NXC-201 BCMA CAR-T in relapsed/refractory AL amyloidosis - Bitget
Immix Biopharma, Inc. Stock 12‑Month Price Target Cut to $20.44, Implies 102% Upside - TradingView
IMMIX BIOPHARMA, INC. : H.C. WAINWRIGHT RAISES TARGET PRICE TO $25 FROM $20 - Bitget
H.C. Wainwright raises Immix Biopharma price target to $25 By Investing.com - Investing.com Australia
H.C. Wainwright raises Immix Biopharma price target to $25 - Investing.com India
Regulatory and Data Risks Loom Over Immix Biopharma’s Clinical Programs and Valuation - TipRanks
Immix Biopharma (NASDAQ:IMMX) Announces Quarterly Earnings Results - MarketBeat
Immix Biopharma (NASDAQ: IMMX) ends Q2 2026 with $232.1M in cash - Stock Titan
Immix Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Immix Biopharma (NASDAQ:IMMX) Stock Price Down 6.7%Here's What Happened - MarketBeat
Immix Biopharma Inc (IMMX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
IMMX Q1 2026 Earnings: 15.25% EPS Surprise on Narrower Loss Despite No RevenueProfit Warning Alert - vinanet.vn
Immix Biopharma (IMMX) Projected to Post Quarterly Earnings on Friday - MarketBeat
IMMX Investors Have Opportunity to Join Immix Biopharma, Inc. Fraud Investigation with SBS Law - Business Wire
Immix Biopharma, Inc. (NASDAQ:IMMX) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Immix Biopharma (IMMX) Advances 5.45% as Biotech Sentiment StrengthensGolden Cross - vinanet.vn
Immix Biopharma faces investigation after hirin... - Pluang
Immix Biopharma, Inc. expected to post a loss of 18 cents a shareEarnings Preview - TradingView
Immix Biopharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference - Investing News Network
Immix Biopharma Announces Participation in Morgan Stanley 24th Annual Global Healthcare Conference and Institutional Investor Meetings - Quiver Quantitative
Janus Henderson Group PLC Boosts Stake in Immix Biopharma, Inc. $IMMX - MarketBeat
IMMX INVESTIGATION: Immix Biopharma Investors Who Lost Money After Reports About Its Former CMO Should Contact Block & Leviton - ACCESS Newswire
Immix Biopharma Inc. (IMMX) Q1 2026 Earnings: EPS Beats Estimates on Lower Loss, Stock Gains 4.65%Earnings Miss Alert - dars.gov.et
Immix Biopharma Inc (IMMX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
IMMX|Immix Biopharma Inc|Price:8.690|Chg%:+0.170 - TradingKey
Immix Biopharma Inc (IMMX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Immix Biopharma Inc (IMMX) Cash Flow - TradingKey
Immix Biopharma (NASDAQ:IMMX) Stock Price Up 9.7%What's Next? - MarketBeat
Immix Biopharma, Inc. Revenue Breakdown – NASDAQ:IMMX - TradingView
Immix Biopharma Inc (IMMX) Income Statement - TradingKey
Immix Biopharma Inc (IMMX) Balance Sheet - TradingKey
Immix Biopharma Inc (IMMX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Immix Biopharma Inc (IMMX) Institutional Confidence - TradingKey
Immix Biopharma Inc (IMMX) Risk Assessment: Volatility, Financial Risk & Investment Risk - tradingkey.com
Immix Biopharma Inc (IMMX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Immix Biopharma Inc (IMMX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
IMMX|Immix Biopharma Inc|Price:10.145|Chg%:+0.425 - TradingKey
Immix Biopharma Inc (IMMX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Immix Biopharma Inc 주식 (IMMX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Morris Gabriel S | CFO |
Dec 10 '25 |
Buy |
6.58 |
770 |
5,067 |
291,429 |
| Rachman Ilya M | CEO and Chairman |
Sep 17 '25 |
Buy |
2.02 |
2,500 |
5,050 |
1,140,937 |
| Morris Gabriel S | CFO |
Sep 16 '25 |
Buy |
1.97 |
2,600 |
5,122 |
290,659 |
0.86%
0.31%
자본화:
|
볼륨(24시간):